Taken together with the previous finding that deletion of Rictor in a mouse model causes no defects in normal prostate function [16], these observations indicate that selective inhibitors of mTORC2 kinase will be valuable as cancer therapeutics. The gene discussed is RICTOR; the disease is cancer.